Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK announced a $10.6 billion all-cash acquisition of Nuvalent at $124 per share, representing a 40% premium. The deal reflects Big Pharma's aggressive capital deployment to address an impending patent cliff, as GSK faces revenue loss from dolutegravir's expiring exclusivity. Nuvalent brings two late-stage kinase inhibitors targeting non-small cell lung cancer with FDA Breakthrough Therapy designations, triggering a short squeeze and signaling potential industry consolidation in oncology.